These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11145519)

  • 1. Parkinson's disease and impaired chemosensitivity to hypoxia.
    Kanda A; Ebihara S; Arai H; Takeda A; Sasaki H
    Lancet; 2000 Dec; 356(9247):2100. PubMed ID: 11145519
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's disease and impaired chemosensitivity to hypoxia.
    Röggla G; Weber W; Röggla M
    Lancet; 2000 Dec; 356(9247):2099. PubMed ID: 11145518
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.
    Kalia LV; Brotchie JM; Fox SH
    Mov Disord; 2013 Feb; 28(2):131-44. PubMed ID: 23225267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?
    Lipworth B
    Ann Allergy Asthma Immunol; 2006 May; 96(5):640-2. PubMed ID: 16729775
    [No Abstract]   [Full Text] [Related]  

  • 5. [Theophylline and selective phosphodiesterase inhibitor in therapy of obstructive respiratory tract diseases].
    Rabe KF; Dent G; Magnussen H
    Pneumologie; 1997 Mar; 51(3):303-16. PubMed ID: 9173421
    [No Abstract]   [Full Text] [Related]  

  • 6. Ultraviolet light induction of skin carcinoma in the mouse; influence of cAMP modifying agents.
    Zajdela F; Latarjet R
    Bull Cancer; 1978; 65(3):305-13. PubMed ID: 214189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline for chronic obstructive pulmonary disease?....Time to move on.
    Rabe KF; Hiemstra PS
    Am J Respir Crit Care Med; 2010 Oct; 182(7):868-9. PubMed ID: 20884941
    [No Abstract]   [Full Text] [Related]  

  • 8. Theophylline-improved swallowing reflex in elderly nursing home patients.
    Ebihara T; Ebihara S; Okazaki T; Takahashi H; Wantando A; Yasuda H; Sasaki H
    J Am Geriatr Soc; 2004 Oct; 52(10):1787-8. PubMed ID: 15450073
    [No Abstract]   [Full Text] [Related]  

  • 9. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?
    Jankovic J
    Ann Neurol; 2008 Mar; 63(3):267-9. PubMed ID: 18383071
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of caffeine on the freezing of gait in Parkinson's disease.
    Kitagawa M; Houzen H; Tashiro K
    Mov Disord; 2007 Apr; 22(5):710-2. PubMed ID: 17373724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immediate results of treatment of psoriasis with phosphodiesterase inhibitors].
    Berenbeĭn BA; Mikhaĭlov GS; Shumaĭ NI
    Vestn Dermatol Venerol; 1979 May; (5):21-5. PubMed ID: 452673
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrotoxicity from contrast media: attenuation with theophylline.
    Morcos SK; Brown PW
    Radiology; 1995 Nov; 197(2):546-7; dicussion 248. PubMed ID: 7480713
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative evaluation of caffeine and theophylline for weaning premature infants from the ventilator.
    Sims ME; Rangasamy R; Lee S; Chung H; Cohen J; Walther FJ
    Am J Perinatol; 1989 Jan; 6(1):72-5. PubMed ID: 2642707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders.
    de Mendonça A; Cunha RA
    J Alzheimers Dis; 2010; 20 Suppl 1():S1-2. PubMed ID: 20448305
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrotoxicity from contrast media: attenuation with theophylline.
    Drescher P; Pereira F; Will JA; Madsen PO
    Radiology; 1995 Nov; 197(2):547-8. PubMed ID: 7480714
    [No Abstract]   [Full Text] [Related]  

  • 16. N-acetylcysteine and/or theophylline as a preventive measure for contrast agent induced nephropathy: we should use better markers for detection of renal function.
    Schultz MJ
    Radiology; 2007 Dec; 245(3):918-9; author reply 918-9. PubMed ID: 18024462
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
    Kalda A; Yu L; Oztas E; Chen JF
    J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex and idiopathic Parkinson's disease.
    Basson R
    Adv Neurol; 2001; 86():295-300. PubMed ID: 11553989
    [No Abstract]   [Full Text] [Related]  

  • 19. A clinical evaluation of chlorphenoxamine with caffeine in the treatment of Parkinson's disease, including a comparison with methixene.
    Strang RR
    J Clin Pharmacol J New Drugs; 1967; 7(4):214-20. PubMed ID: 5340692
    [No Abstract]   [Full Text] [Related]  

  • 20. Respiratory function in Parkinson's disease.
    Shill H; Stacy M
    Clin Neurosci; 1998; 5(2):131-5. PubMed ID: 10785839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.